Announcements
Announcement of change of CEO
1.Date of the board of directors resolution or date of occurrence of the change: 2022/12/30 2.Position (Please enter chairperson or president/general manager): CEO 3.Name of the previous position holder: Michael …
Announcement of change of the spokesperson
1.Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel (CEO, COO, CMO, CSO, etc.), financial officer, accounting officer, corporate governance officer, chief information security officer, research and development …
Announcement of change of Chairman of the Board
1.Date of the board of directors resolution or date of occurrence of the change: 2022/12/30 2.Position (Please enter chairperson or president/general manager): Chairman of the Board 3.Name of the previous …
Announcement of death of Chairman of the Board (Supplementary Statement on the circumstances of his deputy)
1.Date of the board of directors resolution or date of occurrence of the change: 2022/12/29 2.Position (Please enter chairperson or president/general manager): Chairman of the Board, CEO, and spokesperson 3.Name …
Announcement of change of director
1.Date of occurrence of the change: 2022/12/29 2.Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor): natural-person director 3.Title and name of …
Announcement of death of Chairman of the Board
1.Date of the board of directors resolution or date of occurrence of the change: 2022/12/29 2.Position (Please enter chairperson or president/general manager): Chairman of the Board and CEO 3.Name of …
OBI-866 ”Immunogenic/Therapeutic Glycan Compositions And Uses Thereof“ Was Granted By USPTO
1.Date of occurrence of the event:2022/12/23 2.Company name:OBI Pharma Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:Not applicable 5.Cause of occurrence: OBI Pharma …
Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP505, to US FDA
1.Date of occurrence of the event:2022/12/19 2.New drug name or code: Bispecific Antibody, AP505 3.Indication:Bispecific antibody AP505 is a novel cancer immunotherapy developed by AP Biosciences(hereinafter referred to as APBio). …
Announcement on behalf of AP Biosciences that it obtains the Internal Control Special Audit Report by CPA
1.Date on which Internal Control Special Audit Report by CPA was obtained:2022/12/09 2.Date on which the CPA was engaged to conduct the special audit of internal control:2021/07/01~2022/06/30 3.Reason the CPA …
Amendments to related matters that OBI forfeits part of subscription rights of Obigen’s cash capital increase and distributes the rights to its shareholders
1.Date of occurrence of the event:2022/11/28 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios: Not applicable 5.Cause of occurrence: …